Table 1. Comparison of the age-related risks and mean diagnostic ages of the five major VHL lesions in patients with different mutation types.
| Group | Lesion | Age-related Risk | Mean Diagnostic Age | |||
|---|---|---|---|---|---|---|
| HR | 95% CI | p Value | Mean ± SD (year) | p Value | ||
| DEL and NSS group vs M group | CHB | 1.406 | 1.055–1.874 | 0.020 | 29.7 ± 10.6 vs 33.0 ± 11.9 | 0.045 |
| RA | 1.762 | 1.105–2.811 | 0.017 | 29.0 ± 13.0 vs 31.0 ± 13.0 | 0.531 | |
| RCC | 1.671 | 1.179–2.368 | 0.004 | 37.8 ± 11.3 vs 39.9 ± 10.6 | 0.281 | |
| PCT | 1.595 | 1.140–2.230 | 0.006 | 34.6 ± 10.8 vs 38.4 ± 12.4 | 0.056 | |
| M group vs DEL and NSS group | PHEO | 1.947 | 1.015–3.736 | 0.045 | 31.4 ± 14.2 vs 35.7 ± 9.2 | 0.328 |
| DEL group vs M and NSS group | CHB | 1.313 | 0.919–1.875 | 0.135 | 29.8 ± 10.0 vs 31.8 ± 11.7 | 0.329 |
| RA | 1.993 | 1.206–3.291 | 0.007 | 28.6 ± 11.7 vs 30.4 ± 13.5 | 0.597 | |
| RCC | 1.166 | 0.762–1.783 | 0.479 | 38.2 ± 11.5 vs 38.9 ± 10.9 | 0.761 | |
| PCT | 1.352 | 0.901–2.029 | 0.146 | 33.3 ± 9.1 vs 37.2 ± 12.2 | 0.107 | |
| PHEO | 0.555 | 0.218–1.410 | 0.216 | 34.0 ± 10.1 vs 32.6 ± 13.4 | 0.817 | |
| NSS group vs M and DEL group | CHB | 1.253 | 0.911–1.723 | 0.166 | 29.6 ± 11.2 vs 32.1 ± 11.4 | 0.178 |
| RA | 1.087 | 0.643–1.836 | 0.756 | 29.5 ± 14.5 vs 30.0 ± 12.4 | 0.880 | |
| RCC | 1.666 | 1.153–2.407 | 0.007 | 37.6 ± 11.2 vs 39.4 ± 10.9 | 0.381 | |
| PCT | 1.409 | 0.982–2.021 | 0.063 | 35.4 ± 11.8 vs 36.8 ± 11.7 | 0.535 | |
| PHEO | 0.631 | 0.293–1.362 | 0.241 | 36.8 ± 9.2 vs 31.8 ± 13.6 | 0.335 | |
Abbreviations: M, missense mutations; DEL, large deletions of the VHL gene; NSS, nonsense mutations, small deletions and insertions, and splice site mutations; CHB, central nervous system hemangioblastoma; RA, retinal angioma; RCC, renal cell carcinoma; PCT, pancreatic cyst or tumor; PHEO, pheochromocytoma; HR, hazard ration; SD, standard deviation.